Galecto

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.

Fintel reports that Orbimed Advisors has filed a 13D/A form with the SEC disclosing ownership of 2.70MM shares of Galecto Inc (GLTO).

Orbimed Advisors Now Owns 10.5% of Galecto

BOSTON, March 09, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter and year ended December 31, 2022.

Galecto Reports Operating and Financial Results for the Year Ended December 31, 2022

BOSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present and be available for 1x1 meetings at Oppenheimer's 33rd Annual Healthcare Conference taking place virtually on March 13-15, 2023. Details for the event are as follows:

Galecto to Participate in Oppenheimer's 33rd Annual Healthcare Conference

BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming SVB Securities Global Biopharma Conference taking place on February 14-16, 2023. Details for the event are as follows:

Galecto to Participate in SVB Securities Global Biopharma Conference

Intermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Galecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the quarter ended September 30, 2022.

Galecto Reports Third Quarter Operating and Financial Results

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virtual webinar today, Tuesday, November 8th at 8:00 a.m. ET. The study was selected for a late-breaking oral presentation at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2022.

Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present at the upcoming Jefferies London Healthcare Conference taking place on November 15-17, 2022. Details for the event are as follows:

Galecto to Participate in Jefferies London Healthcare Conference

BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. GULLIVER-2 is a clinical trial designed to assess GB1211, an orally available and high-affinity small molecule carbohydrate-based galectin-3 inhibitor, for the treatment of severe liver diseases. Galectin-3 is a pro-fibrotic β-galactoside binding protein highly expressed in fibrotic livers and implicated in severe liver diseases.

Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study a combination of pembrolizumab and a galectin-3 inhibitor Phase 2 investigator-initiated trial to be supported by an NCI grant to Providence Cancer Institute in Portland, Oregon to study a combination of pembrolizumab and a galectin-3 inhibitor

Galecto's Galectin-3 Inhibitor GB1211 to be Studied in Combination with Pembrolizumab in Patients with Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma by Providence Cancer Institute

BOSTON, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it will host a live conference call and webcast at 8:00 am ET on Tuesday, November 8, 2022 to review topline data from the Company's Phase 1b/2a GULLIVER-2 trial for liver cirrhosis.

Galecto to Host Virtual Investor Event and Webcast to Review Topline Data from GULLIVER-2 Trial on Tuesday, November 8, 2022

Company to host a live conference call and webcast today, September 29, 2022, at 8:00 a.m. ET Company to host a live conference call and webcast today, September 29, 2022, at 8:00 a.m. ET

GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that management will be participating at the upcoming H.C. Wainwright's 24th Annual Global Investment Conference taking place on September 12-14, 2022. Details for the event are as follows:

Galecto to Participate at H.C. Wainwright 24th Annual Global Investment Conference

BOSTON, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced a recent publication in the Journal of Cancer Research and Clinical Oncology,1 a peer-reviewed scientific journal, supporting the Company's ongoing clinical programs by reinforcing the foundational galectin-3 biology underlying Galecto's approach to the inhibition of galectin-3 for the treatment of cancer.

Galecto Announces Publication Supporting the Predictive Role of Galectin-3 on Overall Survival of NSCLC Patients in Peer-Reviewed Scientific Journal

BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that management will be participating at the upcoming Jefferies Healthcare Conference, taking place on June 8-10 in New York City. Details for the event are as follows:

Galecto to Participate at Jefferies Healthcare Conference

Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified

Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting

GB0139 is Galecto's proprietary inhaled once-daily small molecule galectin-3 inhibitor

Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of IPF

Top-line results from GULLIVER-2 trial on track for the fourth quarter of 2022

Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

Galecto, Inc. (GLTO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Continued pipeline progress with three potentially first-in-class product candidates

Galecto Reports Financial Results for the Year Ended December 31, 2021

Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease

Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care

GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients

Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial

Roche Holding AG

Galecto Inc (NASDAQ: GLTO) has entered into a clinical trial supply agreement with Roche Holdings AG (OTC: RHHBY) to explore the combination of GB1211 in a planned Phase 2a trial in non-small-cell lung cancer (NSCLC).  Under the agreement terms, Galecto will fund and conduct a Phase 2a trial to investigate the combination of GB1211 and Roche's atezolizumab (Tecentriq) for the treatment of first-line NSCLC.

News for Galecto Stock (GLTO)